<DOC>
	<DOCNO>NCT00003937</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . Chemoprotective drug dexrazoxane may protect normal cell side effect chemotherapy . PURPOSE : Phase III trial study effectiveness three combination chemotherapy regimens plus dexrazoxane treating patient newly diagnose nonmetastatic osteosarcoma .</brief_summary>
	<brief_title>Combination Chemotherapy Plus Dexrazoxane Treating Patients With Newly Diagnosed Nonmetastatic Osteosarcoma</brief_title>
	<detailed_description>OBJECTIVES : I . Compare efficacy three intensification regimen ( doxorubicin v doxorubicin plus ifosfamide v doxorubicin plus ifosfamide etoposide ) patient newly diagnose , previously untreated , nonmetastatic osteosarcoma . II . Determine effect postoperative dose intensification outcome patient standard response preoperative chemotherapy . III . Determine effect dexrazoxane cardioprotection standard induction therapy histologic response patient . IV . Evaluate biological factor may predict outcome patient . V. Determine safety dexrazoxane administer doxorubicin combination cisplatin cisplatin ifosfamide patient . VI . Determine effect dexrazoxane cytotoxicity measure tumor necrosis definitive surgery patient . VII . Assess feasibility administer doxorubicin dexrazoxane cardioprotection high dose ifosfamide etoposide standard risk patient also receive methotrexate cisplatin . OUTLINE : This multicenter study . Patients enrol sequentially 1 3 pilot intensification regimen . After surgery completely remove primary tumor , patient assign 1 2 adjuvant chemotherapy group base percent necrosis limb salvage . Pilot 1 : ( Closed accrual 6/2/2000 ) Patients receive dexrazoxane IV follow immediately doxorubicin IV 20 minute plus cisplatin IV 4 hour day 1 2 week 1 6 . Methotrexate IV 4 hour administer day 1 week 4 , 5 , 9 , 10 . Patients undergo surgery week 11 . Adjuvant chemotherapy begin day 1 week 13 . Group 1 ( good response neoadjuvant chemotherapy ) : Patients receive methotrexate IV 4 hour every 3 week 6 course , begin week 13 . Patients also receive dexrazoxane doxorubicin every 3 week 4 course , begin week 14 . Cisplatin administer first 2 course dexrazoxane doxorubicin . Group 2 ( standard response neoadjuvant chemotherapy ) : Patients receive methotrexate cisplatin group 1 plus dexrazoxane doxorubicin 6 course . Pilot 2 : Patients receive preoperative therapy comprise dexrazoxane , doxorubicin , methotrexate pilot 1 . Ifosfamide IV 4 hour also administer day 1-5 week 1 . Patients undergo surgery week 11 , begin adjuvant chemotherapy week 13 . Group 1 : Patients receive methotrexate , dexrazoxane , doxorubicin pilot 1 , group 1 . Ifosfamide also administer week 14 20 . Cisplatin administer week 17 , 23 , 26 . Group 2 : Patients receive methotrexate , dexrazoxane , doxorubicin pilot 1 , group 2 . Ifosfamide administer week 14 , 20 , 26 , 31 . Cisplatin administer week 17 , 23 , 29 . Pilot 3 : ( Open accrual 6/2/2000 ) Patients receive preoperative therapy comprise methotrexate , dexrazoxane , doxorubicin , ifosfamide , cisplatin pilot 2 . Patients undergo surgery week 11 , begin adjuvant chemotherapy week 13 . Group 1 : Patients receive methotrexate , dexrazoxane , doxorubicin , ifosfamide , cisplatin pilot 2 , group 1 . Group 2 : Patients receive methotrexate week 13 , 19 , 29 , 32 , 35 , 36 , high dose ifosfamide etoposide IV 4 hour day 1-5 week 14 , 23 , 26 , cisplatin week 20 , 30 , 33 . Dexrazoxane doxorubicin administer week 17 , 20 , 30 , 33 . Patients follow every 3 month 1 year , every 6 month 4 year annually thereafter . PROJECTED ACCRUAL : Approximately 180 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Cardiotoxicity</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Dexrazoxane</mesh_term>
	<mesh_term>Razoxane</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove newly diagnose moderate high grade osteosarcoma without metastases No prior treatment , include complete resection No parosteal periosteal sarcoma No osteosarcoma associate Paget 's disease No nonresectable tumor tumor may result marginal interlesion resection Must enrol protocol POG9851 PATIENT CHARACTERISTICS : Age : 30 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,000/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 time normal SGOT great 3 time normal Renal : Creatinine normal Phosphate least 3.0 mg/dL without supplementation Cardiovascular : Shortening fraction least 28 % echocardiogram If echocardiogram unsatisfactory , must ejection fraction least 50 % No history pericarditis myocarditis No symptomatic arrhythmia symptomatic cardiac conduction disturbance PRIOR CONCURRENT THERAPY : See Disease Characteristics Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>localize osteosarcoma</keyword>
	<keyword>cardiac toxicity</keyword>
</DOC>